interleukin

(redirected from Interleukin-13)
Also found in: Thesaurus, Medical, Encyclopedia.

in·ter·leu·kin

 (ĭn′tər-lo͞o′kĭn)
n.
Any of various small proteins that are produced by a variety of cell types, especially T cells and other white blood cells, and that regulate many aspects of inflammation and the immune response, including stimulating the production of white blood cells and platelets.

interleukin

(ˌɪntəˈluːkɪn)
n
(Biochemistry) a substance extracted from white blood cells that stimulates their activity against infection and may be used to combat some forms of cancer

in•ter•leu•kin

(ˈɪn tərˌlu kɪn)
n.
any of a family of small proteins that participate in the body's defense system, esp. by promoting the growth and activation of white blood cells.
[1979; inter- + leuk (ocyte) + -in1; so called because such proteins act as agents of communication between different populations of leukocytes]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.interleukin - any of several lymphokines that promote macrophages and killer T cells and B cells and other components of the immune system
lymphokine - a cytokine secreted by helper T cells in response to stimulation by antigens and that acts on other cells of the immune system (as by activating macrophages)
References in periodicals archive ?
The product is a human monoclonal antibody specifically designed to inhibit signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signalling proteins (cytokines) that contribute to Type 2 inflammation in moderate-to-severe asthma.
The approval of dupilumab--an interleukin-4 and interleukin-13 inhibitor and the first biologic to become available for the treatment of atopic dermatitis--has revolutionized the therapy of adults with moderate to severe disease.
In the CHRONOS study of adults with uncontrolled, moderate to severe AD, patients were treated with the investigational biologic dupilumab (Dupixent), an interleukin-4 and interleukin-13 pathway blocker administered in subcutaneous injections, in combination with topical corticosteroids.
The new drug works by blocking two proteins linked to inflammation, interleukin-4 (IL-4) and interleukin-13 (IL-13).
Some of these changes involved "a protein called interleukin-13 and related intracellular signaling mechanisms," he stated.
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.
Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever.
Heska Corporation (Loveland, CO) has patented canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R.
Results are showing that both allergens produce significant increases in inflammation-related white blood cells in the lungs of the mice, and they elevate blood levels of key markers of allergic reactions, including IgE, interleukin-5, and interleukin-13.
We have previously used this approach to determine the cis/trans chromosomal orientation of the individual nucleotides in SNPs located in the interleukin-13 gene and, thus, the specific allelic haplotypes of that gene (10).